ATE413388T1 - Muskarin antagonisten - Google Patents
Muskarin antagonistenInfo
- Publication number
- ATE413388T1 ATE413388T1 AT03726436T AT03726436T ATE413388T1 AT E413388 T1 ATE413388 T1 AT E413388T1 AT 03726436 T AT03726436 T AT 03726436T AT 03726436 T AT03726436 T AT 03726436T AT E413388 T1 ATE413388 T1 AT E413388T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- formula
- compound
- muscarine antagonists
- methods
- Prior art date
Links
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37609302P | 2002-04-26 | 2002-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE413388T1 true ATE413388T1 (de) | 2008-11-15 |
Family
ID=29270760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03726436T ATE413388T1 (de) | 2002-04-26 | 2003-04-24 | Muskarin antagonisten |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6890936B2 (de) |
| EP (1) | EP1499596B1 (de) |
| JP (2) | JP4527408B2 (de) |
| CN (1) | CN1649845A (de) |
| AT (1) | ATE413388T1 (de) |
| AU (1) | AU2003228674A1 (de) |
| CA (1) | CA2484217A1 (de) |
| DE (1) | DE60324544D1 (de) |
| ES (1) | ES2315494T3 (de) |
| MX (1) | MXPA04010552A (de) |
| WO (1) | WO2003091220A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20084393B (en) | 2003-04-24 | 2008-06-10 | Incyte Corp | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| CN101044134A (zh) * | 2004-09-20 | 2007-09-26 | 塔加西普特公司 | 具有烟碱性胆碱能受体活性的氮杂螺烯和氮杂螺烷化合物 |
| EP2275095A3 (de) * | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
| AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| EP2076288A2 (de) * | 2006-09-22 | 2009-07-08 | Braincells, Inc. | Kombination aus einem hmg-coa-reduktasehemmer und einem zweiten neurogenen wirkstoff zur behandlung einer nervensystemerkrankung und erhöhung von neurogenese |
| WO2008039863A2 (en) * | 2006-09-27 | 2008-04-03 | Braincells, Inc. | Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| SI2091948T1 (sl) | 2006-11-30 | 2012-07-31 | Probiodrug Ag | Novi inhibitorji glutaminil ciklaze |
| CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
| EP2142514B1 (de) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thioharnstoffderivate als glutaminylcyclaseinhibitoren |
| TW200902007A (en) * | 2007-05-25 | 2009-01-16 | Astrazeneca Ab | Spirocyclopropyl piperidine derivatives |
| US20100130477A1 (en) * | 2008-11-25 | 2010-05-27 | Astrazeneca Ab | Spirocyclobutyl Piperidine Derivatives |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| EP2533645B1 (de) | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| KR101790806B1 (ko) | 2010-03-10 | 2017-11-20 | 프로비오드룩 아게 | 글루타미닐 사이클라제(ｑｃ, ｅｃ 2.3.2.5)의 헤테로사이클릭 억제제 |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| WO2011143457A2 (en) | 2010-05-12 | 2011-11-17 | Northwestern University | Compositions and methods for treating or preventing atrial fibrillation |
| WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
| EP2919788A4 (de) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | Verfahren und zusammensetzungen zur behandlung von schizophrenie |
| WO2014144801A1 (en) | 2013-03-15 | 2014-09-18 | Agenebio Inc. | Methods and compositions for improving cognitive function |
| EP3827820A1 (de) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam zur verbesserung der kognitiven funktion |
| DK3212637T3 (da) | 2014-10-31 | 2021-07-12 | Indivior Uk Ltd | Dopamin-d3-receptorantagonistforbindelser |
| CN112843005B (zh) | 2015-05-22 | 2023-02-21 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
| EP3651762B1 (de) * | 2017-07-12 | 2024-07-03 | Vanderbilt University | Antagonisten des muskarinischen acetylcholinrezeptors m4 |
| DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| TWI767148B (zh) * | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04225953A (ja) * | 1990-05-07 | 1992-08-14 | Shionogi & Co Ltd | スピロ ジベンゾスベラン誘導体 |
| GB9309422D0 (en) * | 1993-05-07 | 1993-06-23 | Res Inst Medicine Chem | Chemical compounds |
| WO1999032489A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| CA2444595A1 (en) * | 2001-04-20 | 2002-10-31 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
-
2003
- 2003-04-24 WO PCT/US2003/012694 patent/WO2003091220A1/en not_active Ceased
- 2003-04-24 CN CNA038094436A patent/CN1649845A/zh active Pending
- 2003-04-24 ES ES03726436T patent/ES2315494T3/es not_active Expired - Lifetime
- 2003-04-24 JP JP2003587783A patent/JP4527408B2/ja not_active Expired - Fee Related
- 2003-04-24 MX MXPA04010552A patent/MXPA04010552A/es unknown
- 2003-04-24 AT AT03726436T patent/ATE413388T1/de not_active IP Right Cessation
- 2003-04-24 CA CA002484217A patent/CA2484217A1/en not_active Abandoned
- 2003-04-24 AU AU2003228674A patent/AU2003228674A1/en not_active Abandoned
- 2003-04-24 EP EP03726436A patent/EP1499596B1/de not_active Expired - Lifetime
- 2003-04-24 DE DE60324544T patent/DE60324544D1/de not_active Expired - Lifetime
- 2003-04-28 US US10/425,376 patent/US6890936B2/en not_active Expired - Fee Related
-
2009
- 2009-12-16 JP JP2009285736A patent/JP2010059213A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010059213A (ja) | 2010-03-18 |
| US20040067972A1 (en) | 2004-04-08 |
| ES2315494T3 (es) | 2009-04-01 |
| HK1068136A1 (en) | 2005-04-22 |
| JP4527408B2 (ja) | 2010-08-18 |
| AU2003228674A1 (en) | 2003-11-10 |
| EP1499596A1 (de) | 2005-01-26 |
| EP1499596B1 (de) | 2008-11-05 |
| DE60324544D1 (de) | 2008-12-18 |
| US6890936B2 (en) | 2005-05-10 |
| CN1649845A (zh) | 2005-08-03 |
| JP2006507220A (ja) | 2006-03-02 |
| WO2003091220A1 (en) | 2003-11-06 |
| MXPA04010552A (es) | 2005-01-25 |
| CA2484217A1 (en) | 2003-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE413388T1 (de) | Muskarin antagonisten | |
| IL166271A0 (en) | Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same | |
| UA88012C2 (uk) | Похідні хіназоліндіону як інгібітори parp | |
| SE0101675D0 (sv) | Novel composition | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| ATE425149T1 (de) | ANILINOPYRIMIDIN DERIVATE ALS ßJNK PATHWAY INHIBITORENß, ZUSAMMENSETZUNGEN UND DAMIT VERBUNDENE BEHANDLUNGSMETHODEN | |
| BRPI0410630A (pt) | antagonista de nk1 | |
| ATE478664T1 (de) | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren | |
| ATE453393T1 (de) | Verwendung von pyridylamiden als angiogenesehemmer | |
| IS6658A (is) | Ný efnasambönd | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| DE69725825D1 (de) | 5-HT1F-Agonisten | |
| BR0307833A (pt) | Sìntese controlada de ziprasidona e suas composições | |
| ATE374190T1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| ATE377602T1 (de) | Morphinanderivate und ihre medizinische anwendung | |
| PL376324A1 (en) | Piperazinyl and diazapanyl benzamides and benzthioamides | |
| ATE410203T1 (de) | Lipase-hemmende zusammensetzung | |
| ATE498600T1 (de) | Inden derivate als pharmazeutika | |
| ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
| BG105710A (en) | 5ht1 antagonists for antidepressant therapy | |
| ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
| BR0212899A (pt) | Compostos orgânicos | |
| ATE335739T1 (de) | Cak inhibitoren und deren verwendungen | |
| NO20002408D0 (no) | 5-HT1F antagonister | |
| GB0223223D0 (en) | Organic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |